Search results
Showing 1651 to 1665 of 8910 results
Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
NICE is unable to make a recommendation on tabelecleucel (Ebvallo) for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus. This is because Pierre Fabre Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA923
Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Evidence-based recommendations on using dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome or atrioventricular block.
NICE is unable to recommend panitumumab with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) for previously treated metastatic colorectal cancer in adults. This is because Amgen did not provide an evidence submission.
Show all sections
Sections for TA240
Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
Evidence-based recommendations on burosumab (Crysvita) for X-linked hypophosphataemia in children and young people.
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
In development Reference number: GID-TA10089 Expected publication date: 15 November 2017
In development Reference number: GID-TA10205 Expected publication date: TBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests
In development Reference number: GID-DG10038 Expected publication date: TBC
Awaiting development Reference number: GID-QS10103 Expected publication date: TBC
Awaiting development Reference number: GID-QS10106 Expected publication date: TBC
In development Reference number: GID-QS10113 Expected publication date: TBC
Vulnerable populations: strategies for tackling inequalities
Awaiting development Reference number: GID-QS10124 Expected publication date: TBC
Awaiting development Reference number: GID-QS10129 Expected publication date: TBC
Awaiting development Reference number: GID-QS10130 Expected publication date: TBC